NCT07357311Recruiting
Screening and Care for Fear of Cancer Recurrence in Patients With Cancer at Institut Curie
Fear of Cancer Recurrence: Prevalence, Lived Experience and Satisfaction of Supportive Care Needs in the Hospital Care Pathway. A Mixed Method Study.
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
The goals of this study is to establish the prevalence of severe forms of FCR in the oncology hospital setting, which will require a specific psychotherapeutic response. Two cancer sites are targeted: breast and pulmonary cancers. Secondary objectives include: 1) Determining threshold scores for the FCRI's 9-item severity scale for each type of cancer; 3) To identify a simple item from the FCRI for early detection of FCR in everyday clinical practice, especially using a digital format.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- 8 Sept 2025
- Primary completion date
- 31 Jan 2026
- Lead sponsor
- Institut Curie
- Diseases
- Lung cancer
- NCT number
- NCT07357311
What you commit to
- Study type: Observational
- Planned participants: 200
- From 8 Sept 2025 to the primary completion date, 31 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any social, medical or psychological condition hindering questionnaire completion
Other
- Participating in another patient-reported outcome study interfering with the present study
- Being deprived of personal liberty or under guardianship
Who the study is looking for
- Aged 18 or over
- Clinical or pathological diagnosis of primary or recurrence of a localized/loco-regional or metastatic breast cancer, or a stage 1 or 2, or stage 3 or 4 lung cancer; or a breast or lung cancer metastatic progression
- Three months after completing treatment or three months after the start of a first treatment line for metastatic progression
- Able to comply with the scheduled assessment and interviews
- Able to read and understand the questionnaires' language (i.e. French)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Curie Coordinator of this site? Confirm its status | Paris | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.